Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines
Latest Information Update: 23 Feb 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 11 Dec 2023 Status changed from active, no longer recruiting to completed.
- 16 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2023 Planned End Date changed from 6 Nov 2023 to 20 Nov 2023.